Comparative Pharmacology
Head-to-head clinical analysis: HYDROPRES 25 versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPRES 25 versus TEVETEN HCT.
HYDROPRES 25 vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine uptake, leading to decreased sympathetic outflow.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
1 tablet orally once daily, each tablet contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Dosage may be increased to 2 tablets daily if needed.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hr; reserpine: 50-100 hr (terminal, with prolonged adrenergic depletion lasting days)
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Renal: hydrochlorothiazide 70% unchanged, reserpine ~30% unchanged; fecal: reserpine ~60% metabolites
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category C
Category C
Thiazide Diuretic Combination
ARB + Thiazide Diuretic Combination